VolitionRx prices public offering to raise up to $13.8M to fund product development and clinical studies

The Texas company is actively developing a coronavirus triage test to predict the likelihood that a positive individual will develop complications and severe disease 

VolitionRx - VolitionRx Limited prices public offering to raise up to $13.8 million to support continued product development and clinical studies
The company is offering 4,365,000 shares to the public at $2.75 apiece, with an over-allotment option of 654,750 shares

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Wednesday the pricing of a public offering it hopes will raise up to $13.8 million to support the epigenetics company’s continued product development and clinical studies.

The Austin, Texas-based company is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share.

VolitionRx has also granted the underwriters a 30-day option to purchase up to an additional 654,750 shares at the same public offering price to cover any over-allotments. All the shares are being offered by the company.

READ: VolitionRx to share data on enhanced Nu.Q Capture, Nu.Q Assay performance in detecting lung and blood cancers at ASCO meeting

VolitionRx said it expects to receive gross proceeds, excluding any over-allotments, of $12 million before deducting underwriting discounts and commissions. Assuming the full exercise of the over-allotment option, total gross proceeds to VolitionRx would be $13.8 million.

The company intends to use the money from the offering, that closes on May 22, for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes, including potential strategic acquisitions.

The offering comes as the company actively develops a coronavirus (COVID-19) triage test using its flagship Nu.Q test (normally used to detect cancer biomarkers) to predict the likelihood that a positive individual will develop complications and severe disease. 

It recently conducted a proof of concept study involving 34 COVID-19-positive subjects and 50 control subjects that produced promising results. And preliminary studies of infected patients are now underway in hospitals in Belgium and Germany, with results expected in the second quarter.

VolitionRx said it plans to utilize the results of this trial and other ongoing studies to further its aim of developing a clinically useful product to help in the battle against the COVID-19 global pandemic and potentially other diseases.

National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation (NASDAQ:NHLD), is acting as sole book-running manager for the offering. The Benchmark Company LLC and Maxim Group LLC have acted as financial advisors to the company.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: VolitionRx

Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...


VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read